Prognostic Tomographic Classification of Myopic Choroidal Neovascularization

Area of Science:

• Ophthalmology
• Medical Imaging
• Regenerative Medicine

Background:

• Myopic choroidal neovascularization (mCNV) poses a significant threat to vision.
• Assessing the healing process of mCNV is crucial for predicting visual outcomes.
• Intravitreal ranibizumab is a common treatment for mCNV.

Purpose of the Study:

• To evaluate the prognostic significance of a hyperreflective envelopment in mCNV post-ranibizumab therapy.
• To develop a tomographic classification system for mCNV based on its healing response.

Main Methods:

• Retrospective study of 25 patients with mCNV.
• Classification into Type A (presence of hyperreflective coating) and Type B (absence/partial coating) 1 month after the first ranibizumab injection.
• Assessment of visual acuity and number of injections at 6 and 12 months.

Main Results:

• 60% of patients were classified as Type A, and 40% as Type B.
• Type A demonstrated significantly better visual acuity improvement compared to Type B.
• No significant difference in the number of injections, though Type B trended towards needing more.

Conclusions:

• The proposed tomographic classification of mCNV has potential prognostic value.
• Type A mCNV, characterized by a hyperreflective coating, is associated with superior visual outcomes.
• Further research is warranted to validate these findings in larger cohorts.